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Objectives: Severe reperfusion injury after lung transplantation has mortality rates approaching 40%. The pur-
pose of this investigation was to identify whether our improved 1-year survival after lung transplantation is related
to a change in reperfusion injury.
Methods: We reported in March 2000 that early institution of extracorporeal membrane oxygenation can im-
prove lung transplantation survival. The records of consecutive lung transplant recipients from 1990 to March
2000 (early era, n ¼ 136) were compared with those of recipients from March 2000 to August 2006 (current
era, n ¼ 155). Reperfusion injury was defined by an oxygenation index of greater than 7 (where oxygenation
index ¼ [Percentage inspired oxygen] 3 [Mean airway pressure]/[Partial pressure of oxygen]). Risk factors
for reperfusion injury, treatment of reperfusion injury, and 30-daymortality were compared between eras by using
c2, Fisher’s, or Student’s t tests where appropriate.
Results: Although the incidence of reperfusion injury did not change between the eras, 30-day mortality after lung
transplantation improved from 11.8% in the early era to 3.9% in the current era (P ¼ .003). In patients without
reperfusion injury, mortality was low in both eras. Patients with reperfusion injury had less severe reperfusion injury
(P ¼ .01) and less mortality in the current era (11.4% vs 38.2%, P ¼ .01). Primary pulmonary hypertension was
more common in the early era (10% [14/136] vs 3.2% [5/155], P ¼ .02). Graft ischemic time increased from
223.3  78.5 to 286.32  88.3 minutes in the current era (P ¼ .0001). The mortality of patients with reperfusion
injury requiring extracorporeal membrane oxygenation improved in the current era (80.0% [8/10] vs 25.0%
[3/12], P ¼ .01).
Conclusion: Improved early survival after lung transplantation is due to less severe reperfusion injury, as well as
improvements in survival with extracorporeal membrane oxygenation.
CARDIOTHORACIC TRANSPLANTATIONLung transplantation (LTX) is the preferred treatment for
a variety of patients with end-stage pulmonary diseases.
Primary graft dysfunction (PGD), the most severe form of
ischemia and reperfusion injury (RI), remains the most
common cause of early mortality, accounting for nearly
30% of early deaths after LTX.1 RI is characterized by se-
vere hypoxemia, increased airway pressures, acute pulmo-
nary edema, and frothy endobronchial secretions that
occur within 24 to 48 hours after implantation. In its most
severe form, RI is termed PGD. Despite improvements in
lung preservation and surgical technique, RI continues to
affect 20% to 35% of transplant recipients.1,2 A variety of
factors appear to play a role in the development of RI, in-
cluding graft preservation techniques, graft ischemic time,
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nary contusion, pulmonary embolism, and aspiration.
Supportive therapies, including fluid management, di-
uretic use, and judicious ventilator management, can help
to treat RI, which typically resolves in 48 to 72 hours.
Pulmonary vasodilators, including nitric oxide (NO) and
epoprostenol, have been used in more severe forms of RI.
Patients with severe RI might require extracorporeal mem-
brane oxygenation (ECMO) support.
Early survival after LTX at our institution has improved.
Recent data from the 2006–2007 Scientific Registry of
Transplant Recipients annual report indicates 30-day and
1-year survival at our institution is 98.2% and 92.3%, re-
spectively.3 Because RI is the most common cause of early
death after LTX, we hypothesized that these improved cur-
rent survival rates might be due to a change in RI.
MATERIALS AND METHODS
Patient Population
From January 1990 to August 2006, 291 patients underwent LTX at the
University of Virginia. Data from patients undergoing LTX were extracted
from our Lung Transplant Registry and were approved by the University of
Virginia Institutional Review Board (no. 12006). In March 2000, we re-
ported that a heightened awareness of RI with early institution of ECMO
can improve survival.4 In that report RI was defined as an oxygenation index
(OI) of greater than 7 (where OI ¼ [Fraction of inspired oxygen {FIO2}] 3gery c March 2009
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XAbbreviations and Acronyms
ATGAM ¼ antithymocyte globulin
CMV ¼ cytomegalovirus
COPD ¼ chronic obstructive pulmonary disease
ECMO ¼ extracorporeal membrane oxygenation
FIO2 ¼ fraction of inspired oxygen
ISHLT ¼ International Society for Heart and
Lung Transplantation
LTX ¼ lung transplantation
NO ¼ nitric oxide
OI ¼ oxygenation index
OPO ¼ organ procurement organization
P/F ¼ PaO2/FIO2
PGD ¼ primary graft dysfunction
PPH ¼ primary pulmonary hypertension
RI ¼ reperfusion injury
[Mean airway pressure]/[Partial pressure of oxygen]). OI of greater than 10
is considered severe RI.
Therefore we compared lung transplant recipients before March 2000
(early era, n ¼ 136) with recipients after March 2000 (current era, n ¼
155) to determine whether there has been a change in the incidence, course,
or treatment of RI. Risk factors for RI, treatment of RI, and 30-day mortality
were compared between the early and current eras.
Our LTX database maintains data on characteristics, including age, sex,
ethnicity, body mass index, diagnosis, and cytomegalovirus (CMV) status;
operative events, including single versus double LTX, use of cardiopulmo-
nary bypass (CPB), and graft ischemic time; and postoperative variables, in-
cluding OI and mortality. Our preferred approach for single LTX was
through a standard posterolateral thoracotomy, and that for double LTX
was through a clamshell incision. CPB was used selectively. In 1996, NO
became available at our institution for patients refractory to conventional
ventilator management. Before 1998, donor lung preservation was per-
formed with either Euro–Collins or University of Wisconsin solution. By
2000, lungs were exclusively flushed antegrade and retrograde with Perfa-
dex (Vitrolife, Denver, Colo). All patients had complete follow-up.
Perioperative Immunosuppression and Infection
Prophylaxis
Transplant recipients are started on antibiotics before incision and con-
tinued on antibiotic therapy until bronchial cultures are negative. Recipients
also received 2.5 mg/kg azathioprine and 1 g of methylprednisolone before
organ implantation. Before 2002, patients underwent induction immuno-
suppression consisting of 750 mg of methylprednisolone and antithymocyte
globulin (ATGAM; 7-day taper starting with 15 mg/kg). After 2002, induc-
tion immunosuppression switched from ATGAM to daclizumab (1 mg/kg).
Maintenance immunosuppression consisted of cyclosporine or tacrolimus,
azathioprine (2 mg/kg) or mycophenolate mofetil (2 g), and prednisone
(20 mg). Patients received CMV prophylaxis during the study period with
ganciclovir (3 mg/kg twice daily) or valganciclovir (Valcyte; 900 mg daily;
Roche, Nutley, NJ) from day 7 through day 21. After completion of ganci-
clovir, CMV prophylaxis was maintained with acyclovir (800 mg 4 times
daily). In the setting of donor CMVþ/recipient CMV, ganciclovir was con-
tinued until day 90, and CMV–intravenous immunoglobulin (Cytogam;
Genesis Bio-Pharmaceuticals, Hackensack, NJ) was administered (150
mg/kg on day 4 and weeks 2, 4, 6, and 8 and then 100 mg/kg on weeks
12 and 16).The Journal of Thoracic and CDefinition of RI
There are many scoring systems to determine the severity of PGD or RI
after LTX. The gold standard test to determine this is not readily apparent.
The International Society for Heart and Lung Transplantation (ISHLT) has
developed a grading system based on PaO2/FIO2 (P/F) ratio and infiltrates on
chest x-ray films.5 A P/F ratio of less than 300 with chest x-ray infiltrates is
considered grade 2 PGD, whereas a P/F ratio of less than 200 is considered
grade 3 PGD, the most severe form. Before 1998, our transplant database
maintained OI to determine RI severity. OI as an indicator for severity of
lung injury was developed by critical care physicians and has been used
to stratify patients in the Acute Respiratory Distress Syndrome Network tri-
als.6 The raw data of FIO2, PaO2, and mean airway pressure were not re-
corded for each patient in the early years of our transplant database.
Therefore to compare the early era (before March 2000) with the current
era, OI was used in this study to document the severity of RI. As in our pre-
vious report, RI was defined as an OI of greater than 7.
Statistical Analysis
Statistical comparisons between groups were performed with the Stu-
dent’s t test for continuous variables. c2 Analysis and the Fisher’s exact
test were used, where appropriate, to compare categorical variables. Univar-
iate analysis was performed to identify variables related to RI. A logistic re-
gression model testing the outcome of RI was created by using statistically
significant variables from the univariate analysis.
RESULTS
Patient Population
Preoperative and operative variables during the 2 eras are
shown in Table 1. The mean recipient age increased slightly
from the early to the current era (49.3 12.1 vs 52.2 12.5
years, P ¼ .05). Other variables, including sex, race, body
mass index, and CMV status, were no different between
the 2 eras. Recipient diagnoses had minor but significant dif-
ferences during the eras. a-1 Antitrypsin and primary pul-
monary hypertension (PPH) were more common diagnoses
in the early eras. Operative factors, including the use of
CPB and the incidence of double LTX, were similar. Graft
ischemic times significantly increased from the early era
(223.3  78.5 vs 286.3  88.3 minutes, P ¼ .0001). Com-
paring the early era with the current era, OI was not signifi-
cant. The incidence of RI (as defined by an OI>7) was not
different between the early and current eras (25% vs 22.6%,
P ¼ .63). Severe RI (as defined by an OI>10) was also not
different between the groups (19.9% vs 16.1%, P ¼ .44).
The 30-day mortality for all lung transplant recipients signif-
icantly improved from 11.8% in the early era to 3.9% in the
current era (P ¼ .003).
Influence of RI on Early Mortality
RI remained the most important cause for early mortality,
accounting for 81.3% (13/16) and 66.7% (4/6) of deaths in
the early and current eras, respectively. The mortality of pa-
tients with RI significantly decreased from the early era com-
pared with that seen in the current era (38.2% [13/34] vs
11.4% [4/35], P ¼ .01, Table 2). Only 3 (2.2%) patients
in the early era and 2 (1.3%) patients in the current era with-
out RI died within 30 days of transplantation (P ¼ .67).ardiovascular Surgery c Volume 137, Number 3 689
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Patients with RI in the early and current eras were com-
pared (Table 2). No significant differences in age, diagnoses,
or use of CPB were identified. Patients who had RI in the
current era more commonly underwent double LTX. Sup-
portive treatment, including the use of ECMO, NO, and epo-
prostenol (prostacyclin), was available during both eras. The
use of pulmonary vasodilators (NO and epoprostenol) alone
in patients not requiring ECMO was not significantly differ-
ent between the early and current eras (26.5% [9/34] vs
11.4% [4/35], P ¼ .11). The use of ECMO for patients
with RI did not increase during the study period (early era:
29.4% [10/34] vs current era: 34.3% [12/35], P ¼ .66).
Graft ischemic times increased in patients with RI over
time (242.6  25.4 vs 318  78.5 minutes, P ¼ .0001). In
patients with RI, the severity of OI improved from the early
era compared with that seen in the current era (OI of 24.5 
9.7 vs 18.2  7.4, P ¼ .01).
Patients Treated with ECMO
The overall survival for patients with severe RI requiring
ECMO was 50% [11/22]. These patients were compared by
TABLE 1. Patient demographics, diagnosis, and intraoperative
factors in lung transplant recipients before and after March 2000
Recipient variables
Early era
(n ¼ 136)
Current era
(n ¼ 155)
P
value*
Recipient factors
Age (y) 49.3  12.1 52.2  12.5 .05
Male sex 46.3% (69) 53.5% (83) .63
African American 8.1% (11) 10.3% (16) .51
BMI 24.1  5.6 24.7  4.3 .30
CMV mismatch 25.7% (35) 29.0% (45) .53
Recipient diagnosis
COPD 44.8% (61) 52.9% (82) .17
a1-Antitrypsin 14.0% (19) 4.5% (7) .005
IPF 9.6% (13) 9.0% (13) .89
Sarcoidosis 8.1% (11) 9.0% (14) .78
Cystic fibrosis 7.4% (10) 11.0% (17) .29
Lymphangioleiomyomatosis 0.7% (1) 1.3% (2) .99
Pulmonary fibrosis, other 0.7% (1) 0% (0) .47
Primary pulmonary hypertension 10.3% (14) 3.2% (5) .02
Operative factors
Graft ischemic time 223.3  78.5 286.3  88.3 .0001
Required CPB 19.1% (26) 16.1% (25) .50
Double lung transplantation 22.1% (30) 25.8% (40) .46
Outcomes and mortality
OI 8.7  10.0 6.5  8.3 .06
Significant RI (OI>7) 25% (34) 22.6% (35) .63
Severe RI (OI>10) 19.9% (27) 16.1% (25) .44
30-d Mortality 11.8% (16) 3.9% (6) .003
Categorical data are listed as numbers (percentages). Continuous variables are listed as
means  standard deviation. BMI, Body mass index; CMV, cytomegalovirus; COPD,
chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; CPB, car-
diopulmonary bypass;OI, Oxygenation index. *P values were determined bymeans of
c2 analysis, the Fisher’s exact test, and the Student’s t test, where appropriate.690 The Journal of Thoracic and Cardiovascular Surera (Table 3). The mortality of patients with RI after ECMO
significantly improved from 80% [8/10] in the early era to
25% [3/12] in the current era (P ¼ .01). In the early era
all 5 patients with cystic fibrosis died, whereas 2 patients
with chronic obstructive pulmonary disease (COPD) died.
One of 2 patients with PPH died, and 1 patient with pulmo-
nary fibrosis survived. In the current era 2 of 4 patients with
pulmonary fibrosis died, and 1 of 2 patients with PPH died.
The remainder of the patients survived ECMO. Preoperative
and operative variables, including age, diagnoses, and use of
double LTX, were not different during the 2 eras in patients
treated with ECMO. Importantly, the time to institute
ECMO did not change in the current era. However, the
TABLE 2. Operative variables and outcomes in patients with
reperfusion injury during the 2 eras
Variables
Early era
(n ¼ 34)
Current era
(n ¼ 35)
P
value
Preoperative and operative variables
Age (y) 44.5  15.2 49.0  14.1 .21
Obstructive lung disease 32.4% (11) 42.9% (15) .37
Fibrotic lung disease 50% (17) 45.7% (16) .20
Primary pulmonary hypertension 17.6% (6) 5.7% (2) .15
Required CPB 41.2% (14) 34.3% (12) .55
Double lung transplantation 47.0% (16) 68.6% (24) .02
Treatment and outcomes
Use of NO/epoprostenol 26.5% (9) 11.3% (4) .11
Use of ECMO 29.4% (10) 34.3% (12) .66
Graft ischemic time (min) 242.6  25.4 318  78.5 .0001
OI severity 24.5  9.7 18.2  7.4 .01
Mortality with RI 38.2% (13) 11.4% (4) .01
Categorical data are listed as numbers (percentages). Continuous variables are listed as
means standard deviation.CPB, Cardiopulmonary bypass;NO, nitric oxide; ECMO,
extracorporeal membrane oxygenation; OI, oxygenation index; RI, reperfusion injury.
TABLE 3. Operative variables in patients with reperfusion injury
treated with ECMO
Variables
Early era
(n ¼ 10)
Current era
(n ¼ 12)
P
value
Preoperative and operative variables
Age (y) 41.2  18.6 46.1  12.2 .47
Obstructive lung disease 20% (2) 33.3% (4) .65
Pulmonary fibrosis 10% (1) 33.3% (4) .32
Cystic fibrosis 50% (5) 8.3% (1) .06
Primary pulmonary hypertension 20% (2) 16.6% (2) .99
Double lung transplantation 70% (5) 58.3% (7) .13
Graft ischemic time (min) 270  72.7 309.9  64.2 .19
Factors related to ECMO
Time to institute ECMO (h) 2.5  3.7 4.2  8.6 .57
Duration of ECMO (h) 89  29.8 30.6  8.0 .0001
Venoarterial ECMO 100% (10) 83.3% (10) .48
Mortality 80.0% (8) 25.0% (3) .01
Categorical data are listed as numbers (percentages). Continuous variables are listed as
means  standard deviation. ECMO, Extracorporeal membrane oxygenation.gery c March 2009
Ailawadi et al Cardiothoracic Transplantation
T
Xduration of ECMO was significantly shorter in the current
era (89 29.8 vs 30.6 8.0 hours, P¼ .0001). Venoarterial
ECMO was preferred in both eras to treat RI. Central cannu-
lation of the aorta and right atrium was preferred in cases of
double LTX requiring postoperative ECMO, whereas femo-
ral cannulation was the preferred technique after single LTX.
Pulmonary blood flow is maintained to some degree with
pulsatile flow through the pulmonary artery because bron-
chial blood flow is interrupted in transplanted lungs. Cur-
rently, during ECMO, minimal ventilator settings are used
to avoid secondary ventilator-induced lung injury, patients
are diuresed aggressively, and frequent pulmonary toilet is
performed with bronchoscopy.
Correlation of OI with ISHLT Criteria
A P/F ratio was able to be computed during the current
era. Grade 0 or 1 PGD occurred in 60% (93/155). Grade 2
and 3 PGD occurred in 16.8% (26/155) and 23.2% (36/
155), respectively. Patients with grade 3 PGD were com-
pared with patients with OIs of greater than 7. All but 5 pa-
tients met both criteria. Three patients with grade 3 PGD did
not have an OI of greater than 7, and 2 patients with an OI of
greater than 7 had grade 2 PGD per ISHLT definitions. Im-
portantly, all patients who required ECMO during the cur-
rent era had RI by either criterion. One patient with severe
RI (by both criteria) died without ECMO. The 30-day mor-
tality of Grade 3 PGD in the current era was 11.1% (4/36).
Risk Factors Related to RI
Several variables were evaluated to determine risk factors
related to RI (Table 4). A total of 69 patients during the study
period had RI. Sex did not correlate with RI; however, pa-
tients with RI were younger. Risk factors associated with
RI included longer graft ischemic time, double LTX, fibrotic
lung disease, and PPH. Of 19 patients with PPH during the
study period, 8 had RI, and 4 required ECMO. Patients with
TABLE 4. Variables related to patients with reperfusion injury after
lung transplantation
Variable
Patients without
RI (n ¼ 222)
Patients with
RI (n ¼ 69)
P
value
Recipient age (y) 52.1  11.8 46.8  14.6 .002
Male sex 52.2% (116) 58.0% (40) .41
Graft ischemic time (min) 250.7  67.7 281.0  52.4 .0007
Double lung transplantation (%) 19.8% (44) 39.1% (27) .001
Required CPB 11.3% (25) 37.7% (26) .0001
Obstructive lung disease 63.1% (140) 37.7% (26) .0002
Fibrotic lung disease 32.4% (72) 47.8% (33) .02
Primary pulmonary hypertension 4.5% (10) 13% (9) .0001
Preservation solution
Perfadex 75.3% (64) 24.7% (21) .23
Other 90.0% (18) 10.0% (2)
Categorical data are listed as numbers (percentages). Continuous variables are listed as
means  standard deviation. RI, Reperfusion index; CPB, cardiopulmonary bypass.The Journal of Thoracic and Cobstructive lung disease were negatively correlated with RI.
The use of Perfadex as a preservation solution was not asso-
ciated with RI by means of univariate analysis (Table 4). A
multivariate analysis was performed in an attempt to identify
independent predictors of RI (Table 5). Variables included
in the model were those that were found to have statistically
significant associations with the outcome on univariate anal-
ysis. The model demonstrated modest statistical perfor-
mance (c-statistic ¼ 0.665, R2 ¼ 0.046). Only PPH (odds
ratio, 13.44; P ¼ .04) was found to be an independent pre-
dictor of RI.
DISCUSSION
RI still occurs in 20% to 35% of lung transplant recipi-
ents.1,2 In the present report the incidence of RI as defined
by OI was 22.6% in the current era and was not significantly
less than that in the early era.We noted that the severity of RI
improved during the current era, a finding that is consistent
with other reports. Whitson and colleagues7 reported that the
severity of RI defined by grade 3 PGD decreased over time
from 44% (1992–1998) to 27% (1999–2004).
It has been our observation that early mortality after LTX
is improving. Historically, RI has had an associated mortal-
ity as high as 40% in some series,8 but more recent reports
suggest mortality rates have decreased to 14% to 17% at 90
days.7,9 In our current era we report 30-day mortality rates of
1.8% and 3.9% for lung transplant recipients after 2006 and
for those patients with RI, respectively. There are several
potential explanations for these findings. Over the last 2
decades, several refinements in graft preservation and
surgical technique have been developed and adopted. These
pre-emptive approaches have been discovered to reduce RI.
Pretreatment of the donor lung with prostaglandin E1 be-
fore harvest became routine at our center during the early
era. Although reports documented no effect on RI in a por-
cine single LTXmodel,10,11 other studies have demonstrated
that prostaglandin E1 will dilate the pulmonary vasculature,
decrease RI, and decrease inflammatory cytokines in the
transplanted lung.12,13 The choice of preservation solution
has also changed with time. Several reports have docu-
mented superior preservation with low-potassium dextran
TABLE 5. Multivariate analysis of variables related to reperfusion
injury after lung transplantation
Variable OR (95% CI) P value
Recipient age (y) 0.99 (0.95-1.04) .22
Graft ischemic time (min) 1.00 (0.99-1.01) .22
Double lung transplantation (%) 0.54 (0.12-2.43) .42
Required CPB 2.28 (0.72-7.16) .16
Obstructive lung disease 1.17 (0.37-3.70) .79
Fibrotic lung disease 3.24 (0.81-12.99) .10
Primary pulmonary hypertension 13.44 (1.13-159.27) .04
OR, Odds ratio; CI, confidence interval.ardiovascular Surgery c Volume 137, Number 3 691
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solutions.14-16 Despite conflicting reports that have been
unable to identify protection from RI with these
solutions,17,18 our recent practice has been to solely use Per-
fadex, despite not finding evidence of protection from RI in
the present study. Avoidance of lung hyperinflation during
harvest and lung storage in a canine transplant model has
also been shown to minimize lung injury.19 Controlled grad-
ual reperfusion of the implant has been suggested as a mea-
sure to potentially decrease mechanical disruption of the
pulmonary vascular endothelium and prevent RI20-22; this
has become our standard technique to reperfuse the implant.
Previously, we reported less acute rejection and bronchiolitis
obliterans with the use of daclizumab compared with AT-
GAM.23 Although RI was not evaluated in our previous
study, ATGAM was not administered to patients with evi-
dence of RI. Thus it is unlikely that the induction agent
would have an effect on RI.
In cases in which RI is diagnosed, supportive treatments
include cautious fluid management, diuresis, and avoidance
of ventilator-induced injury. The superiority of low-volume
ventilation is supported by the Acute Respiratory Distress
Syndrome Network24 and likely applies to transplanted
lungs as well. Inhaled NO and prostacyclin have been dem-
onstrated to decrease pulmonary artery pressure and im-
prove the P/F ratio.25,26
When these therapies are insufficient, ECMO can benefit
selected patients. Our preferred approach is venoarterial
ECMO either in the chest or through femoral access because
of concomitant right-sided heart dysfunction from associ-
ated pulmonary hypertension. Meyers and associates27 re-
ported a 58.3% survival to discharge after the use of
ECMO, which is similar to the current findings. We previ-
ously reported that early institution of ECMO (within 2
hours) might be beneficial to successfully treat RI.4 Impor-
tantly, the initiation of ECMO was not more expeditious
in the current era and cannot explain our results. Our pre-
ferred technique of ECMO is central cannulation when pos-
sible to ensure oxygenated blood is being delivered to the
heart and brain. It is likely that a combination of less severe
RI, judicious ventilator management, and program matura-
tion might explain our improved survival with RI and
ECMO.
Variables related to RI by means of univariate analysis in-
cluded graft ischemic time, double LTX, and the diagnoses
of fibrotic lung disease and PPH. Except PPH, there is much
controversy in the literature regarding risk factors for
PGD.28,29 The significance of graft ischemic time has been
debated.29 Inverse correlation of COPD with RI has been
previously reported.28
Limitations
There are several limitations inherent to any single-insti-
tution report. The definition of RI used in this study was692 The Journal of Thoracic and Cardiovascular SuOI and not P/F ratio, as recommended by the ISHLT Work-
ing Group. In this report OI was used as a surrogate because
our method of stratification in the early era was based on OI
and not P/F ratio. The P/F ratio can be inaccurate in deter-
mining the severity of PGD in patients who are not intu-
bated.30 Nonetheless, the ISHLT Working Group has
recently supported using P/F ratio to define the grade of RI.31
Second, the number of patients with RI is admittedly
small, as is the number of patients requiring ECMO. Patients
with RI in the 2 eras did have minor differences. Double
LTX was more common and graft ischemic times were lon-
ger in the current era. PPH was also more common in the
early era. However, patients with PPH who had RI or re-
quired ECMO were few, and this did not explain the differ-
ences in mortality seen between eras. Thus differences in
patient groups alone do not explain the reduction in severity
of RI or improved mortality.
CONCLUSION
Improved early survival after LTX is due to several fac-
tors. In the present era lung RI is less severe, likely because
of several improvements in preservation and surgical tech-
niques, as noted above. The treatment of PGD has also
improved, with better survival seen with ECMO. Collec-
tively, these findings help explain our improved early and
1-year survival after LTX.
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Discussion
Dr Shaf Keshavjee (Toronto, Ontario, Canada). Dr Ailawadi,
that was a very nice presentation. I would like to congratulate your
group on demonstrating significant improvements in the outcome
of LTX in your center.The Journal of Thoracic and CAlthough you have very eloquently explained why you use the
old term ‘‘reperfusion injury’’ and the OI for comparison of your
era outcomes, I think it is very important for the audience to recog-
nize that we need to move toward standardizing nomenclature and
measurement parameters for comparison if we are going to make
meaningful observations in our patients.
I was quite pleased to see in your presentation the reference to
the PGD grading system in your current-era patients. The ISHLT
Working Group defined PGD to refer not only to RI but to acknowl-
edge the fact that much of the syndrome of PGD that you see is
related to donor factors, such as brain death, infection, aspiration,
trauma, and so on, plus ischemia, reperfusion, and the immunologic
factors in the recipient, and therefore that findings that you see
related to improvement of this syndrome after transplantation might
be attributed to many of the factors across the board. I particularly
liked your comment about program maturation because it does
speak to the attributable factor of increasing improvement in
outcomes within the multidisciplinary teams that take care of these
patients with increased volumes and increased experience. I do
think that recipient factors do play a role in what you have seen
because if you look at your data, the table does show that you
have a net increase in lower-risk patients, patients with COPD
and cystic fibrosis, and a net decrease in the higher-risk patients,
patients with pulmonary hypertension and the idiopathic pulmo-
nary fibrosis, and this certainly could contribute to outcomes,
although you might have found that in your small sample size.
Therefore my questions are as follows. Do you know when your
OPO instituted routine administration of steroids to the donors?
This might be a factor in decreasing PGD.
Dr Ailawadi. I do not have the data back in the 1990s when that
was initiated. I do know that it has been the routine in the current era.
Dr Keshavjee. That, again, was a transition that happened in the
late 1990s in most organ procurement organizations (OPO), so that
indeed could have been a factor.
Your study period spans from 1990 to 2006. You chose to split
the eras at March 2000. Why did you choose that date? Second,
your lung preservation solution, as you mentioned, went from
Euro–Collins to University of Wisconsin solution to Perfadex.
Did you look at your data separating Perfadex from the high-potas-
sium solutions, and did you find anything interesting there?
Dr Ailawadi. That is a very good question. We chose March
2000 because that is when we analyzed our previous data and our
last report had come out. That is when we first recognized that early
initiation of ECMO might be beneficial. That might be an arbitrary
date, but it is sort of when wemade that last conclusion and realized
that there might be a difference and became the transition point for
this study. We did not analyze by preservation solution. Again, the
transition point from Euro–Collins or University of Wisconsin
solution started in 1999, and by 2000, we were exclusively using
Perfadex, and that was almost superimposed with the March
2000 transition date. We can go back and look at how preservation
solution related to RI.
Dr Keshavjee. I think for the purpose of the convenience of
analyzing the database, it was probably easier, but it might be
more meaningful to go back and look at that to see what role it
played in your center.
In terms of the ECMO bridge to recovery, your mortality
decreased from 80% to 25%, although the time to institution ofardiovascular Surgery c Volume 137, Number 3 693
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improved outcome? Do you think that you are seeing a different
form or more quickly recoverable form of PGD, or are there factors
in your intensive care unit personnel that might have contributed to
this improvement?
Dr Ailawadi. I think there are multiple potential explanations
that are very difficult in this small sample size to really understand.
I think that the way we handle the ventilator is much different now
than it was in the 1990s based on the Acute Respiratory Distress
Syndrome Network data. I think there is certainly a heightened
awareness of RI or PGD in our intensive care unit, and they might
not have been as aware in the early 1990s. I do think the severity of
the injury to the lung is likely less severe now than it was in the
1990s. Even though we do not see that based on our incidence, I
think the actual amount of injury to the lung has decreased, and
we did try to show that when we analyzed the subgroup of patients
that had RI, their OI was less.
Dr Keshavjee. You demonstrated a significant increase in PGD
in the patients undergoing bilateral LTX. Do you think that this is
real, or is it just that you are more able to diagnose PGD in the
bilateral patients, whereas patients undergoing single LTX have
the advantage of having the residual native lung to provide some
function in some cases.
Dr Ailawadi. That might very well be the case. Obviously the
ISHLT criteria were created for double LTC. It is difficult to tease
that out. That is certainly a possibility.
Dr Keshavjee. Thank you very much.
Dr David M. Follette (Sacramento, Calif). I have 2 questions.
As we moved toward more aggressive use of marginal donors,
donor management strategies changed and improved. Were there
any changes in donor management strategies in your OPO that
might have contributed to having better lungs going in? You
mentioned one that we had talked about many years ago, which
was the use of steroids, but there are other factors that might
have contributed.
Dr Ailawadi. That is also a little bit difficult to tease out. Over-
all, I would say that we seem to be using a lot more marginal donors694 The Journal of Thoracic and Cardiovascular Surnow than we have in the past. Our center has matured and has had
experience with more marginal donors. I probably cannot say that
there is anything that we can pinpoint that is different aside from
OPO changes that have happened across the board at all institu-
tions.
Dr Follette. We found in San Francisco that as we got better at
taking care of marginal donors, we took even better care of the ideal
donors.
The second question is the opposite approach of the last question
our primary discussant asked. You used significantly more double
LTXs in your second cohort, and perhaps some of us felt from Dr
Patterson’s teachings many years ago that double LTXs, well taken
care of, might actually make the duration of your damage shorter.
Do you think part of your excellent result is because you had a sta-
tistically significant increase in the number of double LTXs versus
single LTXs?
Dr Ailawadi. It could be possible, although during the current
era of the study period, only 25% of our LTXs were double
LTXs, and therefore I am not sure whether I can draw that conclu-
sion. This has currently changed at our institution within the last 3
years. More than 60% of our LTXs currently are double LTXs
based on data from the ISHLT reports over the last several years,
suggesting that there is a benefit.
Dr K. Robert Shen (Rochester, Minn). Last year at this meet-
ing, you had reported on less acute rejection, less bronchiolitis
obliterans syndrome, and improved overall survival at your center
after a change in the induction regimen from an ATG-based regi-
men to daclizumab. In your data were you able to assess the effect
of the changes in the induction regimen in the 2 study periods? Do
you have any comment on that?
Dr Ailawadi. The outcomes that we studied in that report
were not 30-day mortality. They were long-term mortality, acute
rejection, and bronchiolitis obliterans syndrome. We did not link
those data with the 30-day data and PGD with this study. Further-
more, ATGAM is not given to patients with evidence of RI or
PGD. I do not think the induction agent played an important
role in RI.gery c March 2009
